Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer

Por Kitai, Hidenori, Ebi, Hiromichi
Publicado no Small GTPases (2016)

Precision Oncology and the Universal Health Coverage System in Japan

Por Ebi, Hiromichi, Bando, Hideaki
Publicado no JCO Precis Oncol (2019)

Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers

Por Ebi, Hiromichi, Boikos, Sosipatros, Faber, Anthony C.
Publicado no J Thorac Dis (2019)

Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Por Ebi, Hiromichi, Faber, Anthony C, Engelman, Jeffrey A, Yano, Seiji
Publicado no Cancer Sci (2014)

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells

Por Tanimoto, Azusa, Yamada, Tadaaki, Nanjo, Shigeki, Takeuchi, Shinji, Ebi, Hiromichi, Kita, Kenji, Matsumoto, Kunio, Yano, Seiji
Publicado em 2014

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report

Por Tanimoto, Azusa, Takeuchi, Shinji, Kotani, Hiroshi, Yamashita, Kaname, Yamada, Tadaaki, Ohtsubo, Koushiro, Ebi, Hiromichi, Ikeda, Hiroko, Yano, Seiji
Publicado no BMC Pulm Med (2018)

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients11

Por Taniguchi, Hiroya, Yamazaki, Kentaro, Yoshino, Takayuki, Muro, Kei, Yatabe, Yasushi, Watanabe, Toshiaki, Ebi, Hiromichi, Ochiai, Atsushi, Baba, Eishi, Tsuchihara, Katsuya
Publicado no Cancer Sci (2015)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells

Por Nanjo, Shigeki, Ebi, Hiromichi, Arai, Sachiko, Takeuchi, Shinji, Yamada, Tadaaki, Mochizuki, Satsuki, Okada, Yasunori, Nakada, Mitsutoshi, Murakami, Takashi, Yano, Seiji
Publicado no Oncotarget (2015)

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition

Por Ebi, Hiromichi, Bando, Hideaki, Taniguchi, Hiroya, Sunakawa, Yu, Okugawa, Yoshinaga, Hatanaka, Yutaka, Hosoda, Waki, Kumamoto, Kensuke, Nakatani, Kaname, Yamazaki, Kentaro
Publicado no Cancer Sci (2020)

Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer

Por Kitai, Hidenori, Ebi, Hiromichi, Tomida, Shuta, Floros, Konstantinos V., Kotani, Hiroshi, Adachi, Yuta, Oizumi, Satoshi, Nishimura, Masaharu, Faber, Anthony C., Yano, Seiji
Publicado no Cancer Discov (2016)

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition

Por Yamazaki, Kentaro, Taniguchi, Hiroya, Yoshino, Takayuki, Akagi, Kiwamu, Ishida, Hideyuki, Ebi, Hiromichi, Nakatani, Kaname, Muro, Kei, Yatabe, Yasushi, Yamaguchi, Kensei, Tsuchihara, Katsuya
Publicado no Cancer Sci (2018)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors

Por Nanjo, Shigeki, Yamada, Tadaaki, Nishihara, Hiroshi, Takeuchi, Shinji, Sano, Takako, Nakagawa, Takayuki, Ishikawa, Daisuke, Zhao, Lu, Ebi, Hiromichi, Yasumoto, Kazuo, Matsumoto, Kunio, Yano, Seiji
Publicado em 2013

Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration

Por TANIMOTO, AZUSA, TAKEUCHI, SHINJI, YAEGASHI, HIROSHI, KOTANI, HIROSHI, KITAI, HIDENORI, NANJO, SHIGEKI, EBI, HIROMICHI, YAMASHITA, KANAME, MOURI, HISATSUGU, OHTSUBO, KOUSHIRO, IKEDA, HIROKO, YANO, SEIJI
Publicado no Mol Clin Oncol (2016)

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

Por Katayama, Ryohei, Khan, Tahsin M., Benes, Cyril, Lifshits, Eugene, Ebi, Hiromichi, Rivera, Victor M., Shakespeare, William C., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T.
Publicado em 2011

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation

Por Nakade, Junya, Takeuchi, Shinji, Nakagawa, Takayuki, Ishikawa, Daisuke, Sano, Takako, Nanjo, Shigeki, Yamada, Tadaaki, Ebi, Hiromichi, Zhao, Lu, Yasumoto, Kazuo, Matsumoto, Kunio, Yonekura, Kazuhiko, Yano, Seiji
Publicado em 2014

Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET

Por Xu, Lu, Kikuchi, Eiki, Xu, Chunxiao, Ebi, Hiromichi, Ercan, Dalia, Cheng, Katherine A., Padera, Robert, Engelman, Jeffrey A., Jänne, Pasi A., Shapiro, Geoffrey I., Shimamura, Takeshi, Wong, Kwok-Kin
Publicado em 2012

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

Por Ebi, Hiromichi, Costa, Carlotta, Faber, Anthony C., Nishtala, Madhuri, Kotani, Hiroshi, Juric, Dejan, Della Pelle, Patricia, Song, Youngchul, Yano, Seiji, Mino-Kenudson, Mari, Benes, Cyril H., Engelman, Jeffrey A.
Publicado em 2013

mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF

Por Ishikawa, Daisuke, Takeuchi, Shinji, Nakagawa, Takayuki, Sano, Takako, Nakade, Junya, Nanjo, Shigeki, Yamada, Tadaaki, Ebi, Hiromichi, Zhao, Lu, Yasumoto, Kazuo, Nakamura, Takahiro, Matsumoto, Kunio, Kagamu, Hiroshi, Yoshizawa, Hirohisa, Yano, Seiji
Publicado em 2013

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

Por Ebi, Hiromichi, Corcoran, Ryan B., Singh, Anurag, Chen, Zhao, Song, Youngchul, Lifshits, Eugene, Ryan, David P., Meyerhardt, Jeffrey A., Benes, Cyril, Settleman, Jeffrey, Wong, Kwok-Kin, Cantley, Lewis C., Engelman, Jeffrey A.
Publicado em 2011

Measurement of PIP(3) Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

Por Costa, Carlotta, Ebi, Hiromichi, Martini, Miriam, Beausoleil, Sean A., Faber, Anthony C., Jakubik, Charles T., Huang, Alan, Wang, Youzhen, Nishtala, Madhuri, Hall, Ben, Rikova, Klarisa, Zhao, Jean, Hirsch, Emilio, Benes, Cyril H., Engelman, Jeffrey A.
Publicado no Cancer Cell (2014)